The correlation between the inflammation of Kager fat pad and clinical phenotype of insertional Achilles tendinitis

The correlation between Kager fat pad inflammatory microenvironment classification and clinical phenotype of insertional Achilles tendinitis based on single cell sequencing

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600125145

Enrollment

Unknown

Registered

2026-05-21

Start date

2026-06-20

Completion date

Unknown

Last updated

2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insertional Achilles tendinitis

Interventions

IAT group (experimental group):None

The healthy group (control group):None

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. IAT group (experimental group) (1) Patients who underwent IAT in our hospital due to persistent symptoms and ineffective conservative treatment; (2) Complete medical records and examination records. 2. Healthy group (control group) (1) Patients without a history of Achilles tendon trauma surgery (such as removal of internal fixation of calcaneal fracture, a small amount of discarded Kager fat pad edge tissue was taken during the operation).

Exclusion criteria

Exclusion criteria: (1) Patients undergoing revision surgery for Achilles tendinopathy; (2) Presence of systemic inflammatory arthritis (such as rheumatoid arthritis) or ankle osteoarthritis (Van Dijk grade > 1); (3) Nervous system diseases; (4) Recent (within 3 months) hormone injection into the ankle joint; (5) Combined with other severe lower limb injuries, or severe chronic diseases (such as uncontrolled diabetes, chronic heart failure); (6) The patient is currently receiving treatment for complications that the investigator considers inappropriate; (7) Patients with a physical or mental disorder that would affect their voluntary participation in the trial (e.g., dementia, severe mental illness, severe visual or hearing impairment, illiteracy, drug addiction); (8) Patients with follow-up time less than 6 months;

Design outcomes

Primary

Measure	Time frame
Differences in the proportion of key cell subsets or specific gene expression signatures in Kager fat pad between different imaging types;	—

Secondary

Measure	Time frame
Correlation between molecular features and clinical symptom scores;Predictive value of molecular signatures for response to previous conservative treatment;Short-term prognosis outcomes;	—

Countries

China

Contacts

Public ContactJieyuan Zhang

Shanghai Sixth People's Hospital

wuzongxiange@126.com+86 158 0092 4754

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026